You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
盤中異動 | 綠葉製藥一度漲超12%創18個月新高,旗下藥物獲FDA上市批準
uSMART盈立智投 01-16 09:49

1月16日,$綠葉製藥(02186.HK)$大幅高開,截止發稿,該股漲超8%,報4.44港元,創18個月新高。

消息面上,該公司昨日公佈,Rykindo®(利培酮緩釋微球注射製劑,亦稱爲LY03004」)已獲美國食品藥品監督管理局(“FDA”)上市批準,用於治療精神分裂症成人患者、以及作爲單藥或作爲鋰鹽或丙戊酸鹽的輔助療法用於雙相障礙I型成人患者的維持治療。除美國市場外,Rykindo®於2021年在中國獲批上市。公司也正在歐洲開發Rykindo®,並計劃將其推廣至全球市場。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account